Nanomedicine: Nanotechnology, Biology and Medicine
Volume 1, Issue 1 , Pages 77-84, March 2005

Camptothecin in sterically stabilized phospholipid micelles: A novel nanomedicine

  • Otilia M. Koo, MD

      Affiliations

    • Department of Biopharmaceutical Sciences, University of Illinois, Chicago, Illinois
  • ,
  • Israel Rubinstein, MD

      Affiliations

    • Department of Biopharmaceutical Sciences, University of Illinois, Chicago, Illinois
    • Department of Medicine, University of Illinois, Chicago, Illinois
    • Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois
  • ,
  • Hayat Onyuksel, PhD

      Affiliations

    • Department of Biopharmaceutical Sciences, University of Illinois, Chicago, Illinois
    • Department of Bioengineering, University of Illinois, Chicago, Illinois
    • Corresponding Author InformationCorresponding author. University of Illinois at Chicago, College of Pharmacy, Department of Biopharmaceutical Sciences (M/C 865), 833 South Wood St, Chicago, IL 60612-7231.

Received 24 September 2004; accepted 18 November 2004.

Abstract 

Background

Camptothecin (CPT) is a well-established topoisomerase I inhibitor against a broad spectrum of cancers. However, poor aqueous solubility, instability, and toxic effects to normal tissues have limited CPT clinical development. Recently, sterically stabilized micelles (SSM) composed of polyethylene glycol (PEGylated) phospholipids have been introduced as safe, biocompatible nanocarriers for the delivery of poorly water-soluble drugs. It was the aim of this study to develop and evaluate in vitro camptothecin-containing SSM (CPT-SSM) as a novel nanomedicine for parenteral administration.

Methods

The solubilization potential, stability, and in vitro cytotoxicity of CPT in SSM were studied. Lyophilization of CPT-SSM under controlled conditions was also studied.

Results

The mean size of CPT-SSM was found to be ∼14 nm with a narrow size distribution. CPT-SSM were prepared by coprecipitation reconstitution. At a concentration of 15 mmol/L of PEGylated phospholipids where no micelle–micelle interaction was observed, CPT solubilization in SSM was 25-fold higher than CPT in buffer. We determined that CPT can be solubilized in SSM up to molar ratios of CPT/lipid = 0.0063:1. Above this critical molar ratio, heterogeneous systems of CPT-SSM and CPT self-aggregated particles were formed. CPT in SSM was at least 3 times more stable and 3-fold more cytotoxic to MCF-7 cells than CPT alone. Furthermore, CPT-SSM alone was lyophilized without additional lyoprotectants and cryoprotectants and reconstituted without any significant change in properties.

Conclusion

We have shown that CPT in SSM is a promising nanomedicine with improved drug solubility, stability, freeze-drying properties, and anticancer activity. It is anticipated that, because of the nanosize and steric stability of the micelles, CPT-SSM will be passively targeted to solid cancers in vivo, resulting in high drug concentration in tumors and reduced drug toxicity to the normal tissues.

Key words: Camptothecin, Phospholipid, Micelles, Formulation, Lyophilization

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 10.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1549-9634(04)00003-6

doi:10.1016/j.nano.2004.11.002

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 1, Issue 1 , Pages 77-84, March 2005